Linagliptin

A highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor with IC50 of 1 nM; no significant inhibition on hERG and muscarinic receptor M1 at 1 uM; shows considerable blood glucose lowering in different animal species.Diabetes Approved (In Vitro) :Linagliptin inhibits DPP-4 activity in vitro in several independent experiments with IC50 values of 0.4, 0.5, 0.9, and 1.1 nM (mean IC50, approximately 1 nM) . Linagliptin inhibits FAP with an IC50 of 89 nM (approximately 90-fold selectivity versus DPP-4) . (In Vivo) :In male Wistar rats, Beagle dogs, and Rhesus monkeys, xanthine linagliptin proves to be a highly efficacious, long-lasting, and potent DPP-4 inhibitor providing >70% inhibition for >7 h for all three species after oral administration of 1 mg/kg. Single oral administration of linagliptin to db/db mice 45 min prior to an oral glucose tolerance test reduced plasma glucose excursion in a dose-dependent manner from 0.1 mg/kg (15% inhibition) to 1 mg/kg (66% inhibition) . Linagliptin (3 and 10 mg/kg) dose-dependently inhibits the DPP-4 enzyme in plasma within 30 min of administration. Linagliptin (1 mg/kg, p.o.) significantly reduces glucose excursion by approximately 50%. Oral administration of the DPP-4 inhibitor linagliptin (3 mg/kg, p.o.) strongly reduces DPP-4 activity, stabilizes active GLP-1 in chronic wounds, and improves healing in ob/ob mice. At day 10 postwounding, linagliptin-treated ob/ob mice show largely epithelialized wounds characterized by the absence of neutrophils.

668270-12-0

BI 1356 | BI-1356 | BI1356

Pharmacology & Drug Discovery

>98% (HPLC)

10 mM in DMSO

O=C (N1CC2=NC (C) =C3C=CC=CC3=N2) N (C) C4=C (N (CC#CC) C (N5C[C@H] (N) CCC5) =N4) C1=O

C25H28N8O2

472.5422

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.